secwatch.observer — SEC 8-K summary
======================================

Issuer:     Context Therapeutics Inc. (CNTX)
CIK:        0001842952
Form:       8-K
Filed at:   2022-03-23T23:59:59+00:00
Accession:  0001842952-22-000028
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Context Therapeutics reports FY2021 net loss of $10.5M; cash $49.7M into 2024
-----------------------------------------------------------------------------

- Cash, equivalents and restricted cash $49.7M at Dec 31, 2021 (vs $0.3M in 2020); expected to fund operations into 2024.
- Net loss of $10.5M for FY2021 vs net income of $6.6M in 2020; R&D expenses $3.8M, G&A $3.6M.
- Closed $31.25M private placement in Dec 2021; $28.75M IPO earlier; pipeline includes three Phase 2 ONA-XR trials and CLDN6 bsAb candidate selection in 2022.
- Appointed Christopher Beck as SVP Operations and Mark Fletcher as VP R&D in Jan 2022.
- Preliminary data expected mid-2022 from first-line metastatic breast cancer and recurrent endometrial cancer trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/0001842952-22-000028-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1842952/000184295222000028/cntx-20220323.htm
  HTML page:      https://secwatch.observer/filing/0001842952-22-000028

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer